Which has better valuation and earnings, PYPD or PALI?

Palisade Bio has higher revenue and earnings than PolyPid. Palisade Bio is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Palisade Bio $250K 1,435.98 -$16.78M -$0.48 N/A

Is PYPD or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Palisade Bio N/A -33.47% -31.79%

Is IKT or PYPD more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% PolyPid N/A -311.08% -150.83%

PolyPid (PYPD) Competitors

$5.15 -0.01 (-0.19%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.16 +0.00 (+0.10%)

As of 09/11/2026 07:30 PM Eastern

Compare

PYPD vs. ENTA, EYPT, PALI, VNDA, and IKT

Should you buy PolyPid stock or one of its competitors? PolyPid's main competitors and comparable companies include Enanta Pharmaceuticals (ENTA), Eyepoint Pharmaceuticals (EYPT), Palisade Bio (PALI), Vanda Pharmaceuticals (VNDA), and Inhibikase Therapeutics (IKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PolyPid compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.87 beat Enanta Pharmaceuticals' score of 0.94 indicating that PolyPid is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Positive
PolyPid	Very Positive

PolyPid has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	5.78	-$81.89M	-$2.41	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

Enanta Pharmaceuticals presently has a consensus target price of $19.50, indicating a potential upside of 50.46%. PolyPid has a consensus target price of $11.33, indicating a potential upside of 120.06%. Given PolyPid's higher possible upside, analysts clearly believe PolyPid is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
PolyPid	N/A	-311.08%	-150.83%

Enanta Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Summary

PolyPid beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PolyPid compare to Eyepoint Pharmaceuticals?

PolyPid (NASDAQ:PYPD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 120.06%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, indicating a potential upside of 507.57%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

PolyPid has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PolyPid has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Eyepoint Pharmaceuticals	$31.37M	11.62	-$231.96M	-$3.74	N/A

In the previous week, Eyepoint Pharmaceuticals had 5 more articles in the media than PolyPid. MarketBeat recorded 6 mentions for Eyepoint Pharmaceuticals and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.27 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Eyepoint Pharmaceuticals	Neutral

PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Summary

Eyepoint Pharmaceuticals beats PolyPid on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to Palisade Bio?

PolyPid (NASDAQ:PYPD) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Palisade Bio has higher revenue and earnings than PolyPid. Palisade Bio is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Palisade Bio	$250K	1,435.98	-$16.78M	-$0.48	N/A

Palisade Bio's return on equity of -33.47% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Palisade Bio	N/A	-33.47%	-31.79%

PolyPid has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 120.06%. Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palisade Bio had 2 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for Palisade Bio and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.87 beat Palisade Bio's score of 1.63 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Palisade Bio	Very Positive

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Palisade Bio beats PolyPid on 11 of the 15 factors compared between the two stocks.

How does PolyPid compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Vanda Pharmaceuticals presently has a consensus target price of $13.70, suggesting a potential upside of 169.16%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 120.06%. Given Vanda Pharmaceuticals' higher possible upside, equities research analysts plainly believe Vanda Pharmaceuticals is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
PolyPid	N/A	-311.08%	-150.83%

PolyPid has lower revenue, but higher earnings than Vanda Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.63	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.87 beat Vanda Pharmaceuticals' score of 1.61 indicating that PolyPid is being referred to more favorably in the news media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Very Positive
PolyPid	Very Positive

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vanda Pharmaceuticals beats PolyPid on 8 of the 14 factors compared between the two stocks.

How does PolyPid compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Inhibikase Therapeutics' return on equity of -42.80% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
PolyPid	N/A	-311.08%	-150.83%

Inhibikase Therapeutics currently has a consensus target price of $5.40, suggesting a potential upside of 130.77%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 120.06%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 1 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.89 beat PolyPid's score of 1.87 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Very Positive
PolyPid	Very Positive

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Inhibikase Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

PolyPid has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,255.86	-$48.26M	-$0.43	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

Summary

Inhibikase Therapeutics beats PolyPid on 9 of the 14 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$98.28M	$12.38B	$7.15B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-3.48	799.75	274.94	25.36
Price / Sales	N/A	966.93	686.57	116.78
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	7.46	10.39	10.33	6.20
Net Income	-$34.17M	$2.85B	$3.50B	$358.50M
7 Day Performance	-4.45%	-3.61%	-3.32%	-2.35%
1 Month Performance	7.74%	0.72%	-0.53%	-3.23%
1 Year Performance	48.41%	3.61%	23.51%	8.79%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	3.3239 of 5 stars	$5.15 -0.2%	$11.33 +120.1%	+48.4%	$98.28M	N/A	N/A	80	Positive News
ENTA Enanta Pharmaceuticals	1.7609 of 5 stars	$13.51 +1.4%	$19.50 +44.3%	+56.5%	$388.24M	$65.32M	N/A	160	Positive News
EYPT Eyepoint Pharmaceuticals	3.3831 of 5 stars	$4.58 +1.8%	$28.11 +513.8%	-68.3%	$387.95M	$31.37M	N/A	120	Gap Down
PALI Palisade Bio	3.1321 of 5 stars	$1.96 +0.5%	$9.00 +359.2%	+244.5%	$339.83M	$250K	N/A	10	Positive News
VNDA Vanda Pharmaceuticals	3.0217 of 5 stars	$5.42 +0.4%	$13.70 +152.8%	+12.9%	$326.50M	$216.10M	N/A	290	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. ENTA, EYPT, PALI, VNDA, and IKT

How does PolyPid compare to Enanta Pharmaceuticals?

Summary

How does PolyPid compare to Eyepoint Pharmaceuticals?

Summary

How does PolyPid compare to Palisade Bio?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Summary

How does PolyPid compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. ENTA, EYPT, PALI, VNDA, and IKT

How does PolyPid compare to Enanta Pharmaceuticals?

Does the media favor ENTA or PYPD?

Which has better valuation & earnings, ENTA or PYPD?

Do analysts rate ENTA or PYPD?

Do institutionals & insiders believe in ENTA or PYPD?

Is ENTA or PYPD more profitable?

Which has more volatility and risk, ENTA or PYPD?

Summary

How does PolyPid compare to Eyepoint Pharmaceuticals?

Do analysts prefer PYPD or EYPT?

Is PYPD or EYPT more profitable?

Do insiders & institutionals have more ownership in PYPD or EYPT?

Which has preferable valuation & earnings, PYPD or EYPT?

Does the media refer more to PYPD or EYPT?

Which has more volatility and risk, PYPD or EYPT?

Summary

How does PolyPid compare to Palisade Bio?

Which has better valuation and earnings, PYPD or PALI?

Is PYPD or PALI more profitable?

Which has more volatility & risk, PYPD or PALI?

Do analysts prefer PYPD or PALI?

Does the media refer more to PYPD or PALI?

Do institutionals & insiders have more ownership in PYPD or PALI?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Do analysts prefer VNDA or PYPD?

Which has more risk and volatility, VNDA or PYPD?

Is VNDA or PYPD more profitable?

Which has stronger valuation & earnings, VNDA or PYPD?

Does the media favor VNDA or PYPD?

Do insiders & institutionals have more ownership in VNDA or PYPD?

Summary

How does PolyPid compare to Inhibikase Therapeutics?

Is IKT or PYPD more profitable?

Do analysts rate IKT or PYPD?

Does the media favor IKT or PYPD?

Do insiders & institutionals hold more shares of IKT or PYPD?

Which has more volatility & risk, IKT or PYPD?

Which has preferable valuation and earnings, IKT or PYPD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools